Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.After the market closed, the Shanghai Municipal Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027). Among them, it is proposed to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials, forming a scale of M&A transactions of 300 billion yuan and activating total assets of over 2 trillion yuan. In addition, the plan also mentioned that the merger of securities companies should be accelerated to build a first-class investment bank.
Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Second, Contemporary Amperex Technology Co., Limited's enlargement trick: special dividends for factories in EuropeFirst, heavy! Shanghai merger and reorganization action plan announced
Second, Contemporary Amperex Technology Co., Limited's enlargement trick: special dividends for factories in EuropeNews:Xinhua News Agency: China's monetary policy has changed from "prudent" to "moderately loose" to send a positive signal.